Shanghai No1 Pharmacy Co Ltd

Shanghai No.1 Pharmacy released its 2026 interim report, with total operating revenue of 982 million yuan and net profit attributable to the parent company of 26.17 million yuan, an increase of 12.15 million yuan compared with the same period last year, up 86.60% year on year. Net cash inflow from operating activities was 21.37 million yuan, ranking sixth among peer companies that have disclosed results. The company's asset-liability ratio was 40.47%, down 4.03 percentage points from the same period last year; gross margin was 15.28%, up 0.58 percentage points from the previous quarter; ROE was 2.34%, up 1.07 percentage points from the same period last year. Diluted earnings per share were 0.12 yuan, up 86.49% year on year. The number of shareholders was 20,500, and the top ten shareholders held 53.74% of total share capital.

First Medicine disclosed an earnings forecast, expecting attributable net profit for the first half of 2026 to be between 23 million yuan and 28 million yuan, a year-on-year increase of 64% to 99.65%. Deducted non-recurring net profit is expected to be between 1.05 million yuan and 1.55 million yuan, a year-on-year decline of 82.8% to 88.35%. The rise in attributable net profit is mainly due to a wholly-owned subsidiary receiving housing expropriation compensation, while the decline in deducted non-recurring net profit is affected by intensified competition in the pharmaceutical distribution industry and new stores still being in the performance growth phase.